Assessing appropriate use of ECAs in clinical trials
Related Insights
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Webinar
Adaptive strategies for more efficient, data-rich and patient-friendly trials
May 28, 2023
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Article
Lessons from China and the United States on the use of RWE in regulatory submissions
Jul 19, 2021
Video
Overcoming asset transfer challenges during a merger and acquisition (M&A)
Oct 20, 2021
Playbook
What emerging trends in the FDA’s most coveted designations might tell us
Feb 8, 2024
Article
Guide for Real-World Evidence
May 21, 2021
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Article
New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle
May 10, 2022
Blog
Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions
May 16, 2022
Article
How RWE can help Biotechs optimize the value of their asset
Apr 5, 2021